We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Powered Deep Learning Model Accurately Counts Cell Types in Whole Slide Images

By LabMedica International staff writers
Posted on 19 Apr 2023

Improved methods for counting cell types in pathology images using deep learning approaches are much needed. More...

Current techniques based on segmentation and regression face challenges such as the necessity for precise pixel-level annotations, difficulties in handling overlapping nuclei or obscured regions, and insufficient information on individual cell type locations. Moreover, probabilistic models tend to yield uncertain predictions and can lead to overconfident predictions. Researchers have now developed an advanced deep learning model to predict and count various cell types in the tumor microenvironment, which is expected to enhance the accuracy and efficiency of cancer diagnostics and treatment planning.

Identifying the different cell types in the tumor microenvironment can offer valuable insights into the tumor's histology and underlying biology. Precise and reliable cell type counting is also crucial for research and clinical applications. In addition, cell counts can be used to study the distribution of different cell types in the tumor microenvironment and its correlation with patient outcomes. In clinical settings, cell counts can help monitor therapy response and track disease progression. Researchers from the University of Eastern Finland (Kuopio, Finland) have proposed a new evidential multi-task deep learning approach, called CT-EMT, to overcome the limitations of current methods for cell type counting in whole slide tumor images. This approach formulates cell type density estimation and cell type counting as regression tasks, and nuclei segmentation as a pixel-level classification task.

The proposed cell type segmentation and counting approach has outperformed state-of-the-art HoVer-Net and StarDist models, with relative improvements of 21% and 12% in terms of mean panoptic quality. The developed model can deliver persuasive interpretations of diverse cell types and can be applied to various computational pathology tasks, such as tumor grading, prognosis, and treatment planning. This work will pave the way for the creation of more accurate and robust digital pathology tools that can support pathologists and clinicians in diagnosing and treating cancer patients.

“The UEF Cancer AI research team aims to explore the potential of using deep learning technology in cancer and health data analysis,” said senior researcher Hamid Behravan of the University of Eastern Finland. “Our study will involve the development and evaluation of cutting-edge deep learning algorithms for analyzing cancer and various types of health-related data, including medical images, genomic data, and electronic health records. We believe that this approach has the potential to significantly improve the accuracy and efficiency of breast cancer diagnosis and treatment planning, as well as to facilitate the discovery of new insights and patterns in cancer data. We hope that our research will contribute to the advancement of precision medicine and the development of more effective and personalized approaches to breast cancer prevention and prognosis.”

Related Links:
University of Eastern Finland


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.